General Information of Drug Combination (ID: DCY41ZS)

Drug Combination Name
Anastrozole BIO-300
Indication
Disease Entry Status REF
Glioma Investigative [1]
Component Drugs Anastrozole   DMNP60F BIO-300   DMJ7NVI
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: SF-295
Zero Interaction Potency (ZIP) Score: 5.11
Bliss Independence Score: 3.86
Loewe Additivity Score: 5.69
LHighest Single Agent (HSA) Score: 6.9

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Anastrozole
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Estrogen-receptor positive breast cancer N.A. Approved [3]
Obesity 5B81 Approved [3]
Anastrozole Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Anastrozole Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Putative sodium-coupled neutral amino acid transporter 7 (SLC38A7) DT2EGUN S38A7_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Anastrozole Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [8]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [8]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [8]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Metabolism [8]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Anastrozole Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Adenylate kinase isoenzyme 1 (AK1) OT614AR3 KAD1_HUMAN Increases ADR [9]
Progesterone receptor (PGR) OT0FZ3QE PRGR_HUMAN Decreases Expression [10]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Decreases Activity [11]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Decreases Activity [12]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Decreases Expression [13]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Decreases Expression [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
Rheumatoid arthritis FA20 Phase 1 [5]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCW1MKK OVCAR3 Investigative [1]
Adenocarcinoma DCWD6PD HCT116 Investigative [1]
Adenocarcinoma DCHR4L5 HT29 Investigative [1]
Adult acute myeloid leukemia DCBDWPI HL-60(TB) Investigative [1]
Adult T acute lymphoblastic leukemia DC9XDVA MOLT-4 Investigative [1]
Anaplastic large cell lymphoma DCXDPNQ SR Investigative [1]
Astrocytoma DCEQNKL U251 Investigative [1]
Childhood T acute lymphoblastic leukemia DC5H0RE CCRF-CEM Investigative [1]
Chronic myelogenous leukemia DCYEZWV K-562 Investigative [1]
Clear cell renal cell carcinoma DC9V2O1 TK-10 Investigative [1]
Clear cell renal cell carcinoma DCNE4OV A498 Investigative [1]
Clear cell renal cell carcinoma DC0NMKL 786-0 Investigative [1]
Cutaneous melanoma DC6WDNA SK-MEL-28 Investigative [1]
Cutaneous melanoma DC0F0W4 SK-MEL-5 Investigative [1]
Glioma DCUCYMK SF-539 Investigative [1]
Glioma DCNNTFC SF-268 Investigative [1]
High grade ovarian serous adenocarcinoma DC3B8AP OVCAR-4 Investigative [1]
Large cell lung carcinoma DCJCC1H NCI-H460 Investigative [1]
Lung adenocarcinoma DC3524J MDA-MB-231 Investigative [1]
Lung adenocarcinoma DC7402G HOP-62 Investigative [1]
Malignant melanoma DCHLZYZ UACC62 Investigative [1]
Malignant melanoma DC9XCKG LOX IMVI Investigative [1]
Melanoma DC7VC4P UACC-257 Investigative [1]
Melanoma DCDTAMI MALME-3M Investigative [1]
Mixed endometrioid and clear cell carcinoma DCO48KT IGROV1 Investigative [1]
Papillary renal cell carcinoma DCZYORF ACHN Investigative [1]
Plasma cell myeloma DC1A20Y RPMI-8226 Investigative [1]
Pleural epithelioid mesothelioma DC0HOY3 NCI-H226 Investigative [1]
Prostate carcinoma DC3WP63 PC-3 Investigative [1]
Breast adenocarcinoma DCRXEXJ MDA-MB-468 Investigative [15]
Carcinoma DC591OB RXF 393 Investigative [15]
Colon adenocarcinoma DCSLGFL COLO 205 Investigative [15]
Colon carcinoma DCDI826 KM12 Investigative [15]
Invasive ductal carcinoma DCT6OP4 HS 578T Investigative [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 34 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5137).
3 Anastrozole FDA Label
4 Clinical pipeline report, company report or official report of Humanetics.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
7 Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. Clin Pharmacol Ther. 2019 Jan 16.
8 In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
9 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
10 Aromatase inhibitors: cellular and molecular effects. J Steroid Biochem Mol Biol. 2005 May;95(1-5):83-9. doi: 10.1016/j.jsbmb.2005.04.010.
11 Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
12 Assessment of Five Pesticides as Endocrine-Disrupting Chemicals: Effects on Estrogen Receptors and Aromatase. Int J Environ Res Public Health. 2022 Feb 10;19(4):1959. doi: 10.3390/ijerph19041959.
13 Inhibition of estrogen receptor reduces connexin 43 expression in breast cancers. Toxicol Appl Pharmacol. 2018 Jan 1;338:182-190. doi: 10.1016/j.taap.2017.11.020. Epub 2017 Nov 24.
14 Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. J Clin Oncol. 2005 Apr 10;23(11):2477-92. doi: 10.1200/JCO.2005.07.559. Epub 2005 Mar 14.
15 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.